The collective public investment in health research and development in the Union reaches about €11 billion per year. However, research for patient-centred health in the EU is fragmented and uncoordinated, negatively affecting innovation, health industries, and the development of new medicines.
The objective of the project is a study on the investment in patient-centred health research and innovation (R&I) providing an illustrative analysis of how patient-centredness is defined, applied, and implemented in the allocation of R&I activities across the EU and MS. It focuses on how funds for health research and innovation are allocated, distributed, and utilised across the EU, post-Covid. It assesses the current applications and outcomes of public health R&I, and proposes policy recommendations to facilitate mainstreaming patient-centeredness in health in the EU and to accelerate innovation in the EU to benefit patients. The presents examples from the EU and its MS showing how public funds are being used to support research prioritising patients over commercial interests.
